Last month, a presentation at the American College of Gastroenterology 2010 Annual Scientific Meeting and postgraduate course, showed a significant stain users have a lower risk of developing colon and rectal cancer.
The presentation was based on a meta-analysis of 22 studies involving more than 2.5 million participants who have used statin drugs. The results indicated that statin can lower the risk of developing colorectal cancer by 12%.
Furthermore, the benefits of statin were greatest among patients with Crohn’s and ulcerative colitis. In those patients, patients who used statin had a 70% reduction in their colon cancer risk compared with patients who didn’t use those drugs.
The National Cancer Institute is considering a large scale, prospective study using rosuvastatin (Crestor, AstraZeneca) to confirm this benefit.
Source: American College of Gastroenterology (ACG) 2010 Annual Scientific Meeting and Postgraduate Course: Poster abstract P1217. Presented October 19, 2010.
Please visit healthreason.com for more health related articles.